Document Detail


Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy.
MedLine Citation:
PMID:  20124178     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Survivors of childhood Hodgkin's lymphoma (HL) are at risk for second malignant neoplasms (SMNs). It is theorized that this risk may be attenuated in patients treated with lower doses of radiation. We report the first long-term outcomes of a cohort of pediatric survivors of HL treated with chemotherapy and low-dose radiation.
PATIENTS AND METHODS: Pediatric patients with HL (n = 112) treated at Stanford from 1970 to 1990 on two combined modality treatment protocols were identified. Treatment included six cycles of chemotherapy with 15 to 25.5 Gy involved-field radiation with optional 10 Gy boosts to bulky sites. Follow-up through September 1, 2007, was obtained from retrospective chart review and patient questionnaires.
RESULTS: One hundred ten children completed HL therapy; median follow-up was 20.6 years. Eighteen patients developed one or more SMNs, including four leukemias, five thyroid carcinomas, six breast carcinomas, and four sarcomas. Cumulative incidence of first SMN was 17% (95% CI, 10.5 to 26.7) at 20 years after HL diagnosis. The standard incidence ratio for any SMN was 22.9 (95% CI, 14.2 to 35) with an absolute excess risk of 93.7 cases per 10,000 person-years. All four secondary leukemias were fatal. For those with second solid tumors, the mean (+/- SE) 5-year disease-free and overall survival were 76% +/- 12% and 85% +/- 10% with median follow-up 5 years from SMN diagnosis.
CONCLUSION: Despite treatment with low-dose radiation, children treated for HL remain at significant risk for SMN. Sarcomas, breast and thyroid carcinomas occurred with similar frequency and latency as found in studies of children with HL who received high-dose radiation.
Authors:
Maureen M O'Brien; Sarah S Donaldson; Raymond R Balise; Alice S Whittemore; Michael P Link
Related Documents :
11330578 - Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity.
7081568 - Preoperative radiation and chemotherapy for anal and rectal cancer.
17170968 - Sinonasal undifferentiated carcinoma: current trends in treatment.
16986298 - Chemo-radiation in advanced nasopharyngeal carcinoma, disease free after 6 years--a cas...
1967148 - High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with ...
19477548 - Structural lung damage after chemotherapy fact or fiction?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-01
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  28     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-25     Completed Date:  2010-03-25     Revised Date:  2011-06-14    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1232-9     Citation Subset:  IM    
Affiliation:
Department of Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 7015, Cincinnati, OH 45229, USA. maureen.obrien@cchmc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Breast Neoplasms / epidemiology
Child
Child, Preschool
Combined Modality Therapy
Female
Hodgkin Disease / therapy*
Humans
Incidence
Male
Neoplasms, Second Primary / epidemiology*,  etiology
Sarcoma / epidemiology
Survivors
Thyroid Neoplasms / epidemiology
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01 CA094069-10/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macroph...
Next Document:  Positron Emission Tomography With [18F]Fluorodeoxyglucose Improves Staging and Patient Management in...